STAGES Trial: Study of Adiposity, Growth and Endocrine Stages

Changes in Adipokines and Adiposity During Puberty and Young Adulthood

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01460784

Acronym

STAGES

Enrollment

575

Registered

2011-10-27

Start date

2010-06-30

Completion date

2015-03-31

Last updated

2015-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Metabolic dysfunction, Insulin resistance, Brown adipose tissue, Dyslipidemia

Brief summary

The investigators propose to conduct a cross-sectional study of 60 participants who are 18-30 years of age to undergo research PET/CT. The purpose of this study is to investigate the relationships between Brown Adipose Tissue (BAT), the adiponectin/leptin (A/L) ratio, and components of the metabolic syndrome in young adults.

Detailed description

We propose to conduct a cross-sectional study of 60 participants who are 18-30 years of age to undergo research PET/CT. The purpose of this study is to investigate the relationships between Brown Adipose Tissue (BAT), the adiponectin/leptin (A/L) ratio, and components of the metabolic syndrome in young adults. This study is part of a larger study aimed at understanding the mechanism of brown adipose tissue as a potential protective factor against metabolic dysfunction.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 30 Years

Healthy volunteers

Yes

Inclusion criteria

* Males and females, 18-30 years of age at enrollment, who are obese (BMI greater or equal to 30 kg/m2, weight less than 159 kg) and healthy * Without medications and endocrine/genetic disorders known to affect weight. * Participants may have insulin resistance, impaired glucose tolerance, dyslipidemia, or hypertension.

Exclusion criteria

* Anyone who refuses participation. * A genetic syndrome or other endocrine disorder known to cause obesity (Prader-Willi, Cushing Syndrome, Leptin deficiency, etc.). * Use of the following medications: psychotropics, sulphonylurea, thiazolidinediones, insulin, glucocorticoids, anti-neoplastic agents, angiotensin receptor blocker, angiotensin-converting enzyme inhibitors. * Pregnancy or history of pregnancy. * Active infectious disease * History of CVD or stroke during the previous 36 months * Total cholesterol 300 mg/dl, triglycerides 400 mg/dl * Blood pressure 140/90 mmHg * Fasting plasma glucose 126 mg/dl. * Diabetes mellitus, type 1 or 2.

Design outcomes

Primary

Measure	Time frame
Presence of brown adipose tissue	2 years

Secondary

Measure	Time frame
Presence of metabolic dysfunction	2 years

Countries

United States

Outcome results